uniQure NV (uniQure NV) FCF Margin % : -741.53% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is uniQure NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. uniQure NV's Free Cash Flow for the three months ended in Mar. 2024 was $-62.92 Mil. uniQure NV's Revenue for the three months ended in Mar. 2024 was $8.49 Mil. Therefore, uniQure NV's FCF Margin % for the quarter that ended in Mar. 2024 was -741.53%.

As of today, uniQure NV's current FCF Yield % is -55.10%.

The historical rank and industry rank for uniQure NV's FCF Margin % or its related term are showing as below:

QURE' s FCF Margin % Range Over the Past 10 Years
Min: -1446.66 Med: -458.82 Max: 51.63
Current: -712.3

During the past 13 years, the highest FCF Margin % of uniQure NV was 51.63%. The lowest was -1446.66%. And the median was -458.82%.

QURE's FCF Margin % is ranked worse than
71.36% of 1044 companies
in the Biotechnology industry
Industry Median: -146.375 vs QURE: -712.30

uniQure NV FCF Margin % Historical Data

The historical data trend for uniQure NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV FCF Margin % Chart

uniQure NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,446.66

-384.69

51.63

-152.84

-966.25

uniQure NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-1,514.44	-2,397.65	2,644.71	-771.10	-741.53

Competitive Comparison of uniQure NV's FCF Margin %

For the Biotechnology subindustry, uniQure NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where uniQure NV's FCF Margin % falls into.

uniQure NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

uniQure NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-153.083	/	15.843
	=	-966.25 %

uniQure NV's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-62.919	/	8.485
	=	-741.53 %

uniQure NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of uniQure NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

uniQure NV (uniQure NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

UQ1:Germany UQ1:Germany

Address

Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP

Website

https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Executives

Walid Abi-saab	officer: Chief Medical Officer	C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Ricardo Dolmetsch	officer: President, R&D	113 HARTWELL AVENUE, LEXINGTON MA 02421
Pierre Caloz	officer: Chief Operating Officer	UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Madhavan Balachandran	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Gut	director	C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post	director
Christian Klemt	officer: Chief Financial Officer	PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Jeremy P. Springhorn	director	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Matthew C Kapusta	director, officer: CEO, Managing Director	7358 MCVAY ROAD, GERMANTOWN TN 38138
Kuta Alexander Edward Iii	officer: Executive VP, Operations	239 WILLIS ROAD, SUDBURY MA 01776